BRPI0812944A2 - Derivados de 6-(pirrolopiridinil)pirimidin-2-ilamina e o uso dos mesmos para o tratamento de câncer e aids - Google Patents

Derivados de 6-(pirrolopiridinil)pirimidin-2-ilamina e o uso dos mesmos para o tratamento de câncer e aids

Info

Publication number
BRPI0812944A2
BRPI0812944A2 BRPI0812944-4A2A BRPI0812944A BRPI0812944A2 BR PI0812944 A2 BRPI0812944 A2 BR PI0812944A2 BR PI0812944 A BRPI0812944 A BR PI0812944A BR PI0812944 A2 BRPI0812944 A2 BR PI0812944A2
Authority
BR
Brazil
Prior art keywords
pyrolopyridinyl
ilamine
pyrimidin
cancer
derivatives
Prior art date
Application number
BRPI0812944-4A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Dieter Dorsch
Margarita Wuchrer
Lars Thore Burgdorf
Christian Sirrenberg
Christina Esdar
Thomas J J Mueller
Eugen Merkul
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0812944A2 publication Critical patent/BRPI0812944A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0812944-4A2A 2007-06-21 2008-05-23 Derivados de 6-(pirrolopiridinil)pirimidin-2-ilamina e o uso dos mesmos para o tratamento de câncer e aids BRPI0812944A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007028515A DE102007028515A1 (de) 2007-06-21 2007-06-21 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
PCT/EP2008/004151 WO2008155000A1 (de) 2007-06-21 2008-05-23 6-(pyrrolopyridinyl)- pyrimidin-2-yl-amin-derivate und ihre verwendung zur behandlung von krebs und aids

Publications (1)

Publication Number Publication Date
BRPI0812944A2 true BRPI0812944A2 (pt) 2014-12-16

Family

ID=39916277

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812944-4A2A BRPI0812944A2 (pt) 2007-06-21 2008-05-23 Derivados de 6-(pirrolopiridinil)pirimidin-2-ilamina e o uso dos mesmos para o tratamento de câncer e aids

Country Status (16)

Country Link
US (1) US8546390B2 (enExample)
EP (1) EP2155745B1 (enExample)
JP (1) JP5411849B2 (enExample)
KR (1) KR20100040862A (enExample)
CN (1) CN101679425B (enExample)
AR (1) AR067081A1 (enExample)
AU (1) AU2008266584B2 (enExample)
BR (1) BRPI0812944A2 (enExample)
CA (1) CA2691223C (enExample)
DE (1) DE102007028515A1 (enExample)
EA (1) EA016160B1 (enExample)
ES (1) ES2533873T3 (enExample)
IL (1) IL202828A0 (enExample)
MX (1) MX2009013341A (enExample)
WO (1) WO2008155000A1 (enExample)
ZA (1) ZA201000432B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078020A4 (en) * 2007-04-10 2011-10-19 Sgx Pharmaceuticals Inc HETEROCYCLIC MODULATORS WITH FUSED CYCLES FOR KINASES
DE102008031517A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102009019962A1 (de) * 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
DE102009060174A1 (de) * 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102009060175A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
DE102010050558A1 (de) * 2010-11-05 2012-05-10 Merck Patent Gmbh 1H-Pyrrolo[2,3-b]pyridinderivate
DE102010053347A1 (de) 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
MD20140130A2 (ro) 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
TWI498325B (zh) * 2013-01-18 2015-09-01 Hoffmann La Roche ３－取代吡唑及其用途
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
NZ630875A (en) * 2013-03-15 2017-12-22 Plexxikon Inc Heterocyclic compounds and uses thereof
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
WO2017161004A1 (en) * 2016-03-15 2017-09-21 University Of South Florida PKCδ INHIBITOR FORMULATIONS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS
EP3442971B1 (en) 2016-04-01 2024-09-25 Recurium IP Holdings, LLC Estrogen receptor modulators
AU2018348241B2 (en) 2017-10-13 2023-01-12 Opna Bio SA Solid forms of a compound for modulating kinases
SG11202110714VA (en) * 2019-04-09 2021-10-28 Plexxikon Inc Condensed azines for ep300 or cbp modulation and indications therefor
JP2022543832A (ja) 2019-08-06 2022-10-14 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 変異体を治療するためのエストロゲン受容体調節剤
CN118772140A (zh) * 2023-04-07 2024-10-15 四川大学 一类化合物及其在治疗hDHODH介导的疾病中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US6265434B1 (en) 1999-04-06 2001-07-24 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
CA2560454C (en) * 2004-03-30 2013-05-21 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
US20080153869A1 (en) * 2004-06-14 2008-06-26 Bressi Jerome C Kinase Inhibitors
WO2006015123A1 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
EP1828180A4 (en) * 2004-12-08 2010-09-15 Glaxosmithkline Llc 1H-pyrrolo [2,3-BETA] PYRIDINE
BRPI0610828A2 (pt) 2005-05-16 2010-07-27 Irm Llc compostos e composições como inibidores de proteìna quinase
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate

Also Published As

Publication number Publication date
DE102007028515A1 (de) 2008-12-24
JP2010530376A (ja) 2010-09-09
ZA201000432B (en) 2010-10-27
JP5411849B2 (ja) 2014-02-12
EA201000004A1 (ru) 2010-06-30
CA2691223A1 (en) 2008-12-24
IL202828A0 (en) 2010-06-30
EP2155745A1 (de) 2010-02-24
AU2008266584B2 (en) 2013-04-04
CN101679425A (zh) 2010-03-24
US20110082140A1 (en) 2011-04-07
KR20100040862A (ko) 2010-04-21
US8546390B2 (en) 2013-10-01
WO2008155000A1 (de) 2008-12-24
AR067081A1 (es) 2009-09-30
MX2009013341A (es) 2010-01-18
EP2155745B1 (de) 2015-01-28
CA2691223C (en) 2015-12-01
CN101679425B (zh) 2013-11-06
ES2533873T3 (es) 2015-04-15
AU2008266584A1 (en) 2008-12-24
EA016160B1 (ru) 2012-02-28

Similar Documents

Publication Publication Date Title
BRPI0812944A2 (pt) Derivados de 6-(pirrolopiridinil)pirimidin-2-ilamina e o uso dos mesmos para o tratamento de câncer e aids
NL301192I2 (nl) Finerenon en zijn zouten, solvaten en solvaten van de zouten daarvan
BRPI0810524A2 (pt) Derivado de (aza)indol e uso do mesmo para propósitos médicos
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0808013A2 (pt) Compostos de quinoxalina e uso dos mesmos
BRPI0812909A2 (pt) Derivados de guanina policíclica e métodos de uso dos mesmos.
BRPI0815811A2 (pt) Derivados de indol substituído e métodos de uso dos mesmos
CR10743A (es) Derivados de azaadamantano y metodos de uso de los mismos
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
BRPI0813355A2 (pt) Compostos de quinazolinona e métodos de uso dos mesmos
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
IL199151A (en) Pyrimidine derivatives, their pharmaceutical preparations, their use in cancer treatment and their kits
BR112012004970A2 (pt) inibidores de jak2 e seu uso para o tratamento de doenças mieloproliferativas e câncer
BRPI0813356A2 (pt) Inibidores de proteína quinase e métodos para uso dos mesmos
BRPI0810208A2 (pt) Combinação de terapias compreendendo inibidores p13k-alpha à base de quinoxalina para uso no tratamento do câncer.
BRPI0810523A2 (pt) Derivado heterocíclico de 5 membros e uso do mesmo para propósitos médicos.
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
BRPI0821424A2 (pt) curativo para tecido mucoso e método de uso
BRPI0717454A2 (pt) Dispositivos implantáveis para o tratamento de incontinência e métodos para o uso dos mesmos
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
BRPI0813828A2 (pt) Compostos antimicrobianos, a síntese dos mesmos e o uso dos mesmos para o tratamento de infecções em mamíferos
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0813457A2 (pt) Composto de organoenxofre contendo halogênio e uso do mesmo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.